Daniel Vargas Pivato De Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel Vargas Pivato De Almeida has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Andrey Soares
Hospital Israelita Albert Einstein, São Paulo, Brazil
2 shared publications - Daniel Herchenhorn
Latin American Cooperative Oncology Group—LACOG, Porto Alegre, Brazil
2 shared publications - Fernando Cotait Maluf
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
2 shared publications Adriano Gonçalves e Silva
Instituto do Câncer e Transplante, Curitiba, PR, Brasil
1 shared publicationAlexandre Saad Fere Lima Pompeo
Hospital Beneficência Portuguesa, Departamento de Uro-Oncologia, São Paulo, SP, Brasil; Grupo de Uro-Oncologia do Hcor, São Paulo, SP, Brasil
1 shared publicationAlvaro Sadek Sarkis
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, SP, Brasil
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500767
Structural Inequities in Global Oncology: Latin America and Caribbean Representation at the ASCO Genitourinary Cancers Symposium (2021-2025)
PURPOSE: Speaker roles at major international oncology meetings mark academic visibility and leadership, yet representation of Latin America and Caribbean (LAC)–affiliated investigators remains poorly characterized. We evaluated LAC-affiliated faculty appearances at the ASCO Genitourinary Cancers Symposium (ASCO GU) from 2021 to 2025. METHODS: We systematically reviewed ASCO GU programs (2021-2025). Eligible sessions included General Session, Oral Abstract Session, and Rapid Oral Abstract Session. Affiliation was determined by institutional listing. We recorded total faculty appearances and stratified faculty appearances into invited educational, abstract-linked, and leadership roles. We additionally examined discussant and moderator appearances separately and identified the assigned speaker for each Oral or Rapid Oral presentation with at least one LAC-affiliated author. RESULTS: Among 84 eligible sessions comprising 540 faculty speakers, only six LAC-affiliated faculty appearances were identified, representing only 1% of the total faculty. No LAC-affiliated faculty appeared in 2021 or 2022, with minimal representation in subsequent years (2023: n = 1; 2024: n = 2; 2025: n = 3). By contrast, LAC-affiliated investigators were identified in 53 appearances as authors or coauthors in Oral or Rapid Oral sessions, predominantly affiliated with institutions in Brazil, Argentina, Chile, Mexico, and Colombia. Three of six LAC-affiliated faculty were linked to specific clinical trial presentations rather than independent educational lectures. CONCLUSION: LAC-affiliated investigators remain markedly under-represented among ASCO GU faculty despite robust scientific contributions, highlighting potential structural inequities and the need for deliberate initiatives to support equitable participation in international scientific discourse.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (7) , e2500767
Open AccessStructural Inequities in Global Oncology: Latin America and Caribbean Representation at the ASCO Genitourinary Cancers Symposium (2021-2025)
PURPOSE: Speaker roles at major international oncology meetings mark academic visibility and leadership, yet representation of Latin America and Caribbean (LAC)–affiliated investigators remains poorly characterized. We evaluated LAC-affiliated faculty appearances at the ASCO Genitourinary Cancers Symposium (ASCO GU) from 2021 to 2025. METHODS: We systematically reviewed ASCO GU programs (2021-2025). Eligible sessions included General Session, Oral Abstract Session, and Rapid Oral Abstract Session. Affiliation was determined by institutional listing. We recorded total faculty appearances and stratified faculty appearances into invited educational, abstract-linked, and leadership roles. We additionally examined discussant and moderator appearances separately and identified the assigned speaker for each Oral or Rapid Oral presentation with at least one LAC-affiliated author. RESULTS: Among 84 eligible sessions comprising 540 faculty speakers, only six LAC-affiliated faculty appearances were identified, representing only 1% of the total faculty. No LAC-affiliated faculty appeared in 2021 or 2022, with minimal representation in subsequent years (2023: n = 1; 2024: n = 2; 2025: n = 3). By contrast, LAC-affiliated investigators were identified in 53 appearances as authors or coauthors in Oral or Rapid Oral sessions, predominantly affiliated with institutions in Brazil, Argentina, Chile, Mexico, and Colombia. Three of six LAC-affiliated faculty were linked to specific clinical trial presentations rather than independent educational lectures. CONCLUSION: LAC-affiliated investigators remain markedly under-represented among ASCO GU faculty despite robust scientific contributions, highlighting potential structural inequities and the need for deliberate initiatives to support equitable participation in international scientific discourse.
- Open Access
- 10 September 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (2) , e58-e69
“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”
- 10 September 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (2) , e58-e69
Open Access“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”
- 1 September 2019
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 141, 163-173
Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials
- 1 September 2019
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 141, 163-173
Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials